LY-334370 is a selective serotonin 5-HT1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals. It is closely related to tryptamines like the psychedelic drug dimethyltryptamine (DMT), but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.
LY-334370 is a selective serotonin 5-HT1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals. It is closely related to tryptamines like the psychedelic drug dimethyltryptamine (DMT), but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.
==See also== Triptan Piperidinylindole Substituted tryptamine § Related compounds CP-135807 Lasmiditan SN-22
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).